JP2021036882A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021036882A5 JP2021036882A5 JP2020185772A JP2020185772A JP2021036882A5 JP 2021036882 A5 JP2021036882 A5 JP 2021036882A5 JP 2020185772 A JP2020185772 A JP 2020185772A JP 2020185772 A JP2020185772 A JP 2020185772A JP 2021036882 A5 JP2021036882 A5 JP 2021036882A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- amino acid
- ctl epitopes
- ctl
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 102000004169 proteins and genes Human genes 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 241000701022 Cytomegalovirus Species 0.000 claims 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- -1 EBNA3A Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- 101150078891 BRLF1 gene Proteins 0.000 claims 1
- 101150009389 BZLF1 gene Proteins 0.000 claims 1
- 101150059079 EBNA1 gene Proteins 0.000 claims 1
- 102000011786 HLA-A Antigens Human genes 0.000 claims 1
- 108010075704 HLA-A Antigens Proteins 0.000 claims 1
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims 1
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012904604 | 2012-10-19 | ||
| AU2012904604A AU2012904604A0 (en) | 2012-10-19 | Improved human cytomegalovirus immunotherapy protein |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018207238A Division JP6846396B2 (ja) | 2012-10-19 | 2018-11-02 | 改良されたヒトヘルペスウイルス免疫療法用タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021036882A JP2021036882A (ja) | 2021-03-11 |
| JP2021036882A5 true JP2021036882A5 (enExample) | 2021-07-26 |
| JP7110302B2 JP7110302B2 (ja) | 2022-08-01 |
Family
ID=50487350
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015537084A Pending JP2015533366A (ja) | 2012-10-19 | 2013-10-21 | 改良されたヒトヘルペスウイルス免疫療法 |
| JP2018010690A Pending JP2018075034A (ja) | 2012-10-19 | 2018-01-25 | 改良されたヒトヘルペスウイルス免疫療法 |
| JP2018207238A Active JP6846396B2 (ja) | 2012-10-19 | 2018-11-02 | 改良されたヒトヘルペスウイルス免疫療法用タンパク質 |
| JP2020185772A Active JP7110302B2 (ja) | 2012-10-19 | 2020-11-06 | 改良されたヒトヘルペスウイルス免疫療法用タンパク質 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015537084A Pending JP2015533366A (ja) | 2012-10-19 | 2013-10-21 | 改良されたヒトヘルペスウイルス免疫療法 |
| JP2018010690A Pending JP2018075034A (ja) | 2012-10-19 | 2018-01-25 | 改良されたヒトヘルペスウイルス免疫療法 |
| JP2018207238A Active JP6846396B2 (ja) | 2012-10-19 | 2018-11-02 | 改良されたヒトヘルペスウイルス免疫療法用タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9901632B2 (enExample) |
| EP (3) | EP3466980A3 (enExample) |
| JP (4) | JP2015533366A (enExample) |
| CN (2) | CN118359733A (enExample) |
| AU (2) | AU2013332272B2 (enExample) |
| CA (1) | CA2889064A1 (enExample) |
| WO (1) | WO2014059489A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015533366A (ja) | 2012-10-19 | 2015-11-24 | ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ | 改良されたヒトヘルペスウイルス免疫療法 |
| WO2016183153A1 (en) * | 2015-05-12 | 2016-11-17 | Memorial Sloan Kettering Cancer Center | Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy |
| CN105030047A (zh) * | 2015-08-31 | 2015-11-11 | 捷赛厨电（北京）科技有限公司 | 可控制油烟的炒锅 |
| AU2017300096A1 (en) * | 2016-07-18 | 2019-02-07 | The Council Of The Queensland Institute Of Medical Research | Multivirus-specific T cell immunotherapy |
| BR112020012361A2 (pt) * | 2017-12-20 | 2020-11-24 | Glaxosmithkline Biologicals S.A. | constructos de antígeno do vírus epstein-barr |
| US20210393684A1 (en) * | 2018-05-18 | 2021-12-23 | The Council Of The Queensland Institute Of Medical Research (Qimr) | Adoptive T-Cell Therapy for CMV Infection and CMV-Associated Diseases |
| EP4458419A3 (en) | 2018-09-10 | 2025-01-08 | Atara Biotherapeutics, Inc. | Methods for expanding antigen-specific car-t cells, compositions and uses related thereto |
| US11810904B2 (en) | 2020-02-24 | 2023-11-07 | PlayNitride Display Co., Ltd. | Micro light emitting diode structure and manufacturing method thereof and micro light emitting diode device |
| CN111394376B (zh) * | 2020-03-30 | 2023-04-28 | 济宁医学院 | 一种融合基因bfna、重组腺病毒及其制备方法和应用 |
| MX2022013490A (es) * | 2020-04-28 | 2023-01-05 | Council Queensland Inst Medical Res | Composicion de la vacuna de poliepitopo contra citomegalovirus humano. |
| CA3192632A1 (en) * | 2020-10-07 | 2022-04-14 | The Council Of The Queensland Institute Of Medical Research | Herpesvirus polyepitope vaccines |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPM446594A0 (en) | 1994-03-16 | 1994-04-14 | Csl Limited | Cytotoxic t-cell epitopes identified within epstein-barr virus |
| US6703024B2 (en) * | 1996-05-24 | 2004-03-09 | The Council Of The Queensland Institute Of Medical Research | EBV CTL epitopes |
| AUPO007396A0 (en) | 1996-05-24 | 1996-06-20 | Csl Limited | Ebv ctl epitopes |
| AUPO784197A0 (en) | 1997-07-10 | 1997-08-07 | Csl Limited | Treatment of nasopharyngeal carcinoma |
| US7005131B1 (en) * | 1999-08-13 | 2006-02-28 | The Rockefeller University | Protective antigen of Epstein Barr Virus |
| CA2394748A1 (en) | 1999-12-28 | 2001-07-05 | Epimmune Inc. | Optimized minigenes and peptides encoded thereby |
| AUPR593101A0 (en) * | 2001-06-26 | 2001-07-19 | Council Of The Queensland Institute Of Medical Research, The | Cytomegalovirus t cell epitopes |
| AU2002950183A0 (en) * | 2002-07-12 | 2002-09-12 | The Council Of The Queensland Institute Of Medical Research | Expression of hydrophobic proteins |
| US7507803B2 (en) | 2002-10-03 | 2009-03-24 | Genimmune N.V. | Optimized multi-epitope constructs and uses thereof |
| WO2004041849A1 (en) * | 2002-11-07 | 2004-05-21 | The Council Of The Queensland Institute Of Medical Research | Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor |
| EP1651666B1 (en) | 2003-07-11 | 2009-05-27 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
| WO2006056027A1 (en) * | 2004-11-29 | 2006-06-01 | The Council Of The Queensland Institute Of Medical Research | Human cytomegalovirus immunotherapy |
| CN101213199B (zh) * | 2005-06-30 | 2013-12-18 | 卫材R&D管理有限公司 | 用于制备免疫佐剂的化合物 |
| WO2010014567A2 (en) * | 2008-08-01 | 2010-02-04 | Merck & Co., Inc. | Variant hcmv pp65, ie1, and ie2 polynucleotides and uses thereof |
| US9402917B2 (en) * | 2009-04-03 | 2016-08-02 | Duke University | Methods for the induction of broadly anti-HIV-1 neutralizing antibody responses employing liposome-MPER peptide compositions |
| KR101450958B1 (ko) | 2009-04-30 | 2014-10-15 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 폐렴구균 백신 및 그의 용도 |
| BR112013017488A2 (pt) * | 2011-01-06 | 2017-08-01 | Bionor Immuno As | peptídeos imunogênicos multiméricos e monoméricos |
| JP2015533366A (ja) | 2012-10-19 | 2015-11-24 | ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ | 改良されたヒトヘルペスウイルス免疫療法 |
-
2013
- 2013-10-21 JP JP2015537084A patent/JP2015533366A/ja active Pending
- 2013-10-21 CN CN202410527083.3A patent/CN118359733A/zh active Pending
- 2013-10-21 EP EP18207655.4A patent/EP3466980A3/en not_active Withdrawn
- 2013-10-21 EP EP21157985.9A patent/EP3872097A1/en active Pending
- 2013-10-21 US US14/436,239 patent/US9901632B2/en active Active
- 2013-10-21 EP EP13847496.0A patent/EP2909238A4/en not_active Withdrawn
- 2013-10-21 CA CA2889064A patent/CA2889064A1/en active Pending
- 2013-10-21 WO PCT/AU2013/001216 patent/WO2014059489A1/en not_active Ceased
- 2013-10-21 AU AU2013332272A patent/AU2013332272B2/en active Active
- 2013-10-21 CN CN201380065495.XA patent/CN104918960B/zh active Active
-
2018
- 2018-01-02 US US15/860,145 patent/US11065329B2/en active Active
- 2018-01-25 JP JP2018010690A patent/JP2018075034A/ja active Pending
- 2018-11-02 JP JP2018207238A patent/JP6846396B2/ja active Active
- 2018-12-06 AU AU2018274961A patent/AU2018274961A1/en not_active Abandoned
-
2020
- 2020-11-06 JP JP2020185772A patent/JP7110302B2/ja active Active
-
2021
- 2021-04-09 US US17/226,929 patent/US11896665B2/en active Active
-
2023
- 2023-12-21 US US18/393,160 patent/US20240156953A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021036882A5 (enExample) | ||
| Cohen | Vaccine development for Epstein-Barr virus | |
| Khanna et al. | Vaccine strategies against Epstein‐Barr virus‐associated diseases: lessons from studies on cytotoxic T‐cell‐mediated immune regulation | |
| Ruiss et al. | A virus-like particle-based Epstein-Barr virus vaccine | |
| Khanna et al. | Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. | |
| Jonjić et al. | A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection | |
| CN100526331C (zh) | 来自ebv的ctl表位 | |
| Yang et al. | Virus-induced polyclonal cytotoxic T lymphocyte stimulation. | |
| Moss et al. | The immunology of Epstein–Barr virus infection | |
| Elkington et al. | Cross‐reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H | |
| Zarling et al. | Herpes simplex virus (HSV)-specific human T-cell clones recognize HSV glycoprotein D expressed by a recombinant vaccinia virus | |
| Dasari et al. | Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases | |
| JP2019511921A5 (enExample) | ||
| WO1995024925A1 (en) | Cytotoxic t-cell epitopes | |
| Cai et al. | Prophylactic and therapeutic EBV vaccines: Major scientific obstacles, historical progress, and future direction | |
| Mühe et al. | Non-human primate lymphocryptoviruses: past, present, and future | |
| Wang et al. | The use of an E1-deleted, replication-defective adenovirus recombinant expressing the rabies virus glycoprotein for early vaccination of mice against rabies virus | |
| Yue et al. | Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques | |
| Lockey et al. | Epstein-Barr virus vaccine development: a lytic and latent protein cocktail | |
| Khanna et al. | Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells | |
| CN115894708B (zh) | 一种人巨细胞病毒抗原表位嵌合肽及其应用 | |
| JP2000511522A (ja) | Ｅｂｖ ｃｔｌ エピトープ | |
| WO2025082236A1 (zh) | 识别ebv抗原的t细胞受体及其应用 | |
| Carter et al. | Intratypic and intertypic specificity of lymphocytes involved in the recognition of herpes simplex virus glycoproteins | |
| Grose | Glycoproteins of varicella-zoster virus and their herpes simplex virus homologs |